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Summary 
Rats were kindled by intraperitoneal injection of pentylenetetra- 
zol (PTZ) (30 mg/Kg) every 48 h. Once kindled, some of the animals 
received a single injection of cysteamine (200 mg/Kg). Somatos- 
tatin-like immunoreactivity (SLI) and 125 I-Tyr II -somatostatin 
binding were measured in the frontoparietal cortex and hippocampus 
of the two experimental groups and the control rats. After PTZ 
kindling the following was observed: i) SLI content was increased 
in the two areas; 2) Somatostatin receptor affinity decreased 
in the frontoparietal cortex and was unaltered in the hippocampus; 
3) The number of somatostatin receptors decreased in the hippocampus 
and was unaltered in the frontoparietal cortex. Cysteamine, an 
agent which depletes brain somatostatin and suppresses kindled 
seizures in PTZ-treated rats, reversed the altered SLI levels 
and binding in these rats. 
"Kindling" refers to an experimental model of epilepsy in which repeated 
administration of a subconvulsive dose of a drug (pentylenetetrazol, cocaine, 
carbachol and lidocaine) or electrical current induces a progressive intensi- 
fication of seizure activity, that culminates with a generalized seizure 
(1-6). Although the phenomenon of kindling has been extensively investigated, 
the basic biochemical mechanism underlyng the development and maintenance 
of this effect is still unclear. 
It has been suggested that the peptide somatostatin, a possible neuro- 
transmitter or neuromodulator in the central nervous system (7), may play 
a role in kindling processes (8-11). It was recently reported that the 
levels of somatostatin-like immunoreactivity (SLI) are decreased in the 
rat brain, particularly in the striatum, by the injection of a single convul- 
sant dose of pentylenetetrazol (PTZ) (12). Moreover, Assouline et al.(ll) 
have demonstrated that seizures in pentylenetetrazol-kindled rats are sup- 
pressed following systemic administration of cysteamine ( B -mercaptoethyl- 
amine), an agent which causes depletion of brain and gastrointestinal SLI 
(13). These results suggest that changes in endogenous brain SLI and/or 
receptors may be critically involved in the kindled state. To test this 
hypothesis, we used two approaches. First, we determined the effect of 
the repeated administration of subconvulsant doses of pentylenetetrazol 
on somatostatin levels and receptor number in rat frontoparietal cortex 
and hippocampus. Secound, the effect of cysteamine on the same parameters 
in rats which had been subjected to repetitive systemic administration 
of subconvulsive doses of pentylenetetrazol. 
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Materials and Methods 
Chemicals. 
The origin of the chemicals used was the same as in (14). Pentylenetetra-  
zol and cysteamine were purchased from Sigma (St. Louis, M.O. U.S.A.). 
Tyr l l -somatostat in was radioiodinated by the chloramine-T method (15). Specif ic 
radioactivity of the tracer was about 850 Ci/g. The rabbit antibody used 
in the radioimmunoassay technique was purchased from the Radiochemical  Center 
(Amersham, U.K.). This antiserum was raised in rabbits against somatostat in-14 
conjugated to bovine serum albumin and is specif ic for somatostatin, but 
since somatostat in-14 also constitutes the C-terminal port ions of somatosta- 
tin-25 and somatostatin-28, it does not dist inguish between the three forms. 
Experimental animals. 
Adult Sprague Dawley rats init ial ly weighing approximately 230 g, were 
divided into three groups. PTZ kindl ing was achieved through administrat ion 
of subconvulsant PTZ doses (30 mg/2ml 0.9% NaCI/Kg i.p.) every 48 h. as 
previously described (16). This schedule avoided drug accumulat ion because 
the half- l i fe of PTZ in the rat is less than 4 h (17). The control group 
was injected with an equivalent volume of saline on a similar schedule. 
After PTZ injection, the behaviour of the animals was observed for 20-25 
min. Behavioural  changes were recorded and classi f ied according to a seizure 
ranking system (16). In all animals, the first PTZ injection did not have 
any obvious convulsive effect. The severity of subsequent responses increased 
progressively, and all animals exhibited a fully developed seizure between 
7th and 20th PTZ injection as previously described (ii). The animals were 
sacrif iced 44 days after the first PTZ or saline injection. In the third 
group, a single intraperitoneal injection of cysteamine (200 mg/Kg) was 
administred intraperitoneally,  24 h after the last PTZ injection, and the 
animals were sacri f iced 3 days later. 
Tissue extract ion and somatostat in radioimmunoassay. 
Somatostat in was extracted from both the frontoparietal  cortex and 
hippocampus fol lowing the method of Patel and Reicbl in (18), and since the 
yield of the overall  extract ion procedure was about 85% in the two brain 
areas studied, the recovery of somatostatin was similar in both brain areas. 
Protein was determinated by the method of Lowry et al. (19). Immunoreactive 
somatostatin levels were measured by a modif ied specif ic radio immunoassay 
method (18), with a sensit ivity l imit of i0 pg/ml. Incubation tubes prepared 
in tr ipl icate contaneid i00 Z i samples of unknown or standard solutions 
of 0-500 pg cyclic somatostatin tetradecapeptide di luted in phosphate buffer 
(0.05 M, pH 7.2 containing 0.3 % bovine serum albumin, 0.01 M EDTA), 
200 ~ i  appropriately di luted ant i -somatostat in serum, i00 Z i freshly prepared 
1251-Tyrl l  -somatostat in di luted in buffer to give 6000 cpm (equivalent to 
5-10 pg), and enough buffer to give a final volume of 0.8 ml. All reagents 
and assay tubes were kept chi l led in ice before the 48 h incubation at 4~C. 
Separation of bound and free hormone was accompl ished by addit ion of i ml 
dextran-coated charcoal (dextran 0.2 % w/v; charcoal 2 % w/v). Di lut ion 
curves for each brain area were paral lel  to the standard curve. The intra- 
and inter-assay variat ion coeff ic ients were 6.5 % and 8.1 % respectively. 
Binding assay on membrane preparations. 
Synaptosomal membranes from the frontoparietal  cortex and hippocampus 
were prepared as described by Reubi et al. (20). The specif ic binding of 
125I-Tyr II -somatostat in to synaptosomal membranes from frontoparietal  cortex 
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and hippocampus was performed according to the modified method of Czernik 
and Petrack (21). Briefly, the binding assay was conducted under standard 
conditions at SO~C in 250 ~ i of a medium consisting of 50 mM Tris-HCl buffer 
(pH 7.5), 5 mM MgClp, 0.2 % bovine serum albumin and 0.i mg/ml bacitracin 
with 250 pM 125 l-Tyr-ll-somatostatin (up to i0 nM). The reaction was initiated 
by the addition of synaptosomal membranes (i.5 mg protein/ml). After a 
60 min incubation, membrane-bound peptide was separated by centrifugation 
and the radioactivity determined. Nonspecific binding was obtained from 
the amount of radioactivity bound in the presence of I~TM somatostatin and 
represented about 25 % of the binding observed in the absence of unlabelled 
peptide. This nonspecific component was subtracted from the total bound 
radioactivity in order of obtain the corresponding specific binding. The 
inactivation of 125 l-Tyrl l-somatostatin in the incubation medium after expo- 
sure to membranes was studied by observing the ability of the peptide to 
rebind to fresh membranes (22). 
Statistical analysis. 
Individual experiments were performed in duplicate. All results are 
given as the means + SEM, and the statistical significance of the differences 
between groups was calculated by Student's "t" test. 
Results 
The rate and pattern of PTZ-kindling in the rats were similar to those 
described previously (Ii). Table i shows that the SLI content in fronto- 
parietal cortex and hippocampus of PTZ-kindled rats is significantly higher, 
when compared with controls. Cysteamine administration returned the concentra- 
tion of cortical and hippocampal SLI to control levels in PTZ-kindled rats. 
Table 1 
Influence of pentylenetetrazol (PTZ) and pentylenetetrazol 
plus cysteamine treatment on somatostatin-like immunoreacti- 
vity (SLI) levels in the frontoparietal cortex and bippocampus. 
Results are expressed in ng somatostatin/mg protein as the 
mean + SEM. 
Groups Frontoparietal cortex Hippocampus n 
Control 6.01 + 0.37 5.60 + 0.20 5 
PTZ 11.15 + 1.05(*) 8.48 + 0.45(*) 5 
I 
PTZ plus cysteamine 7.14 + 0.70 5.99 + 0.50 5 
Statistical significance :~ p < 0.005 vs control value. 
Brain plasma membranes of both control and experimental groups bound 
125 l -Tyr l l -somatostat in in a time-dependent fashion; an apparent equilibrium 
was observed between 50-180 min at 30~C (data not shown). All subsequent 
binding studies were, therefore, conducted at 30~C for 60 min. To rule out 
the possibility of different somatostatin-degrading activities in the membrane 
preparations that might affect the interpretation of results, the degradation 
of the peptide was determined (22). Membranes from both brain areas showed 
a similar peptide degradation capacity (10-12 %) in all cases. 
Increasing concentrations of unlabelled somatostatin competitively 
inhibited the specific binding of 1251-Tyr i hsomatostat in  to brain membrane 
preparations from both the experimental groups and the control group (Fig.l, 
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left panels). However, the specific binding of the tracer on brain membranes 
in the PTZ-kindled group was significantly lower than that in the control 
animals in both the absence and presence of unlabelled somatostatin throughout 
the whole range of concentrations studied. 
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Fig.l 
Influence of pentylenetetrazol (PTZ) and pentylenetetrazol 
plus cysteamine treatment on somatostatin binding to (A) 
frontoparietal cortex and (B) hippocampal membranes. Left panel, 
membranes (1.5 mg protein/ml) were incubated for 60 min 
at 30~C in the presence of 125i_Tyr ll_somatostatin (125 I- 
-Tyr ii -SS) and increasing concentrations of native peptide. 
Values for control ( Q ), PTZ-treated ( 0 ) and PTZ-and- 
cysteamine-treated (~)  animals are expressed as the mean 
SEM of five replicate experiments. Right panel, Scatchard 
analysis of the same data. 
To determine whether this decrease in specific binding exibited by 
PTZ-kindled rats was due to a change in either the affinity or the number 
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of receptors, the stoichiometric data were interpreted by the method of 
Scatchard (23). These studies revealed that there was a decrease in the 
number of specific somatostatin receptors in the hippocampus and an increase 
in the dissociation constant in the frontoparietal cortex of PTZ-kindled 
animals (Fig.l, right panels and Table 2). Scatchard analysis indicated 
a single class of receptors; the Kd values were in the nanomolar range. 
Table 2 
The effect of PTZ and PTZ plus Cysteamine treatment on speci- 
fic somatostatin receptors in rat frontoparietal cortex 
and hippocampus. 
GROUPS 
BRAIN AREAS 
FRONTOPARIETAL CORTEX HIPPOCAMPUS 
CONTROL 
Kd(nM) 0.325 + 0.02 0.249 + 0.02 
Bmax 248 + i0 235 + 12 
PTZ 
Kd(nM) 0.496 + 0.04(~) 0,207 + 0.03 
Bmax 226 + 9 161 + 9(~) 
PTZ plus cysteamine 
Kd(nM) 0.277 + 0.04 0.278 + 0.04 
Bmax 216 + 18 233 + 19 
Binding parameters were obtained by Scatchard (23) analysis 
of data from rigth panels in Fig.l. Bmax, Binding capacity 
(femtomoles of somatostatin bound per mg protein). Values 
represent the mean + SEM of five rats in each group. 
p <0.005 vs. control. 
Cysteamine injection led to a suppression of PTZ-induced seizures in 
PTZ-kindled rats. This treatment completely reversed the increased SLI content 
and decreased somatostatin binding levels that had been induced by PTZ-kind- 
ling (Fig. 1 and Table 2). 
Discussion 
This study indicates that PTZ-kindling increased SLI levels in the 
frontoparietal cortex and hippocampus while it decreased the apparent affinity 
of somatostatin receptors in the frontoparietal cortex and the number of 
somatostatin receptors in the hippocampus. These effects are reversed by 
a single dose of cysteamine. 
The frontoparietal cortex and hippocampus were selected for analysis 
because of the evidence that the histopathological changes in PTZ-kindled 
rats are concentrated in these brain areas (24). In addition, the somatostatin 
levels and receptor numbers are high in these regions (12,25,26). 
The somatostatin levels in both brain areas as well as the binding 
parameters of brain somatostatin receptors in control rats were similar 
to those previously reported by others (12,25,26). It should be mentioned 
that the Scatchard analysis suggested a single receptor population. This 
feature agrees with some studies (12,21,27), but differs from other previously 
reported data (28,29). It is conceivable that use of reduced smaller somatos- 
tatin analogs (28) or their labelling with very different isotopes (29) 
might explain this inconsistancy. 
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The reason for the elevated somatostatin levels in the frontoparietal 
cortex and hippocampus of rats kindled by PTZ remains obscure. It has pre- 
viously been reported that a single-dose of PTZ did not change the somatos- 
tatin content in rat cerebral cortex and hippocampus (12), while in kindling, 
induced either electrically or pharmacologically, somatostatin was increased 
in the cortical and subcortical areas of the rat brain (9,10). In addition 
to somatostatin, changes in the cathecolaminergic (30), cholinergic (31) 
and GABAergic (32) systems have been found after PTZ seizures. Furthermore, 
enkephalins, dynorphin and thyrotropin-releasing hormone levels, (but not 
those of B-endorphin), are elevated in the brains of kindled rats (33,34,35). 
It might be that in the kindled state there is an increased release 
of somatostatin in addition to the high content of brain somatostatin. In 
this regard, Pitkanen et al.(S6) have shown that after PTZ-induced generalized 
convulsion the amount of SLI released into cisternal cerebrospinal fluid 
was higher in kindled rats than in controls. In general, if the release 
of ligand increases, the number of receptors for the ligand decreases over 
time by down regulation and we did detect a decrease of somatostatin receptors 
in the hippocampus of PTZ-kindled rats. In this regard, recent data has 
indicated that hypothalamic somatostatin release causes a reduction in the 
number of somatostatin receptors in rat pituitary membranes (87). It has 
been also shown that preincubation of pituitary tumor cells with somatostatin 
results in a marked decrease of the number of somatostatin receptors (38). 
Thus, regulation of somatostatin receptors appears to be similar to that 
of other hormone-receptor systems (39-41). However, increasing site occupancy 
has been shown to be accompained by decreased affinity in a variety of hor- 
mone-receptor systems (42), as was also found in this study at the cortical 
level. 
Higuchi et ai.(43) have shown that the number of somatostatin receptors 
in amygdala kindling are decreased in the hippocampus. Therefore, in the 
hippocampus both electrically stimulated amygdaloid (43) and PTZ kindling 
lead to somatostatin receptor changes which result in a decreased 125 l-- 
Tyrl l  -somatostatin binding. Similar changes in this brain structure, known 
to be highly susceptible to seizure-producing stimuli (1-6), suggest that 
lowering the number of somatostatin receptors in this brain region may take 
part in the development of kindled seizures. 
The receptor alterations found in the frontoparietal cortex after 
PTZ kindling in the present study are opposite to the changes found after 
amygdaloid kindling by Higuchi et ai.(43). Who found a significant increase 
in somatostatin receptor density after amygdaloid kindling. These previous 
findings together with present results suggest that differing mechanisms 
operate in response to different seizure-inducing stimuli in the fronto- 
parietal cortex. 
The present data together with the lack c f significant changes in 
the number and affinity of somatostatin receptors after the acute seizures 
induced by Pitkanen et al.(12) suggest that the changes in somatostatin 
receptor binding after PTZ kindling were not related to seizure sequelae. 
It has been shown that cysteamine-induced depletion of brain and stomach 
somatostatin is associated with up-regulation of the respective cerebro- 
cortical and gastric somatostatin receptors (44,45). We have noted that 
following intraperitoneal injection of cysteamine, there is complete inhibi- 
tion of seizures in PTZ-kindled rats. These results are consistent with 
the previous findings of Assouline et al (ii). These authors demonstrated 
that this effect is actually related to an influence of cysteamine on the 
"kindled state", and not to an anticonvulsant property of the drug itself. 
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The tzme course of the cysteamine influence in PTZ-kindled rats is similar 
to the time course reported for cysteamine-induced depletion of brain immuno- 
reactive somatostatin (13). On the other hand, cysteamine reversed the changes 
in the somatostatin levels and binding in PTZ-kindled rats. 
These data also provide evidence to support the hypothesis that somatos- 
tatin receptors play a role in PTZ-kindled seizure development. If the de- 
creased 125 i_Tyrll -somatostatin binding found following PTZ kindling is 
a reflection of a functional subsensitivity, then the present data lend 
support to the view that a decrease in response to somatostatin, a central 
nervous system depressing neurotransmiter (46-48), may be a general mechanism 
involved in the development of increased seizure susceptibility. 
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